Distribution of Brimonidine into Anterior and Posterior Tissues of Monkey, Rabbit, and Rat Eyes

Abstract

ABSTRACT:The objectives of the study were to evaluate the distribution of brimonidine (␣ 2 -adrenergic agonist) into anterior and posterior ocular tissues. Single or multiple doses of a 0.2 or 0.5% brimonidine tartrate solution were administered to one or both eyes of monkeys or to one eye of rabbits. Brimonidine was administered intraperitoneally to rats. After topical administration, [14 C]brimonidine was rapidly absorbed into the cornea and conjunctiva and distributed throughout the eye. [ 14 C]Radioactivity was higher and cleared more slowly in pigmented tissues (iris/ciliary body, choroid/retina, and optic nerve) than in nonpigmented tissues. Single and multiple dosing led to a similar drug distribution, with higher levels of brimonidine measured in pigmented tissues after multiple dosing. Most of the radioactivity extracted from ocular tissues represented unchanged brimonidine. In the rabbits and the monkey treated in only one eye, levels of radioactivity in the untreated eye were low, consistent with the low systemic levels and rapid drug clearance. Posterior ocular tissue concentrations of radioactivity exceeded systemic blood concentrations. The vitreous humor brimonidine concentrations in monkeys treated topically with 0.2% brimonidine tartrate was 82 ؎ 45 nM. Vitreous levels in rabbits confirmed the penetration of brimonidine to the posterior segment. Similar concentrations of brimonidine (22 to 390 nM) were measured in the vitreous and retina of rats injected intraperitoneally with brimonidine. Both topically applied and systemically administered brimonidine reach the back of the eye at nanomolar concentrations sufficient to activate ␣ 2 -adrenergic receptors. The brimonidine levels achieved at the retina are relevant for neuroprotection models.Brimonidine (AGN 190342 1 ; Fig. 1) is a highly selective ␣ 2 -adrenergic agonist approved for the treatment of open-angle glaucoma. Glaucoma represents a family of ocular diseases characterized by a progressive optic neuropathy and loss of retinal ganglion nerve cells (Adkins and Balfour, 1998). One of the primary risk factors for glaucoma is elevated intraocular pressure. When applied to the eye, brimonidine activates ␣ 2 -adrenergic receptors, resulting in decreased aqueous humor production and increased uveoscleral outflow (Toris et al., 1995). These effects on aqueous humor dynamics lead to a reduction in intraocular pressure.Laboratory studies with brimonidine suggest that activation of ␣ 2 -receptors in the retina and/or optic nerve can promote the survival of retinal ganglion nerve cells (David, 1998). Studies show that intraperitoneal and topical administration of brimonidine promoted retinal ganglion cell survival after calibrated optic nerve compression and ischemia/reperfusion in animal models of neuronal injury Yoles et al., 1999;Donello et al., 2001). Importantly, if the ocular instillation of brimonidine promotes retinal ganglion cell survival in glaucomatous neuropathy, then a new therapeutic approach to glaucoma management may be indicated in ...

Ability of Poly-<small>L</small>-arginine to Enhance Drug Absorption into Aqueous Humor and Vitreous Body after Instillation in Rabbits

“…1). The observed kinetic pattern was consistent with those obtained in previous studies after single instillations of bunazosin, 16) flunarizine, 17) brimonidine, 18) and timolol. 19) In the presence of PLA at 5 mg/ml, pyridoxamine and FD-4 concentrations at 30 min after single instillation were increased 29-and 16-fold, respectively (Fig.…”

Intraocular distribution of topically applied hydrophilic and lipophilic substances in rat eyes

“…Previous studies have shown that for topically applied drugs, the route of drug delivery to ciliary body and retina is through conjunctiva and sclera. Since these tissues have rich network of capillaries, it is likely that in our study, the presence of dye in these tissues is subsequent to systemic absorption (Chien et al, 1990;Acheampong et al, 2002).…”

Efeito hipotensor de três formulações diferentes do tartarato de brimonidina em olhos normais

“…Já foi descrito que a pigmenta ção iriana pode influenciar no efeito de drogas antiglaucomatosas, pois tecidos pigmentados obtiveram maior concentração da droga, e redução mais lenta da mesma (27,28) . Em seu estudo Kim et al, relata que a durabilidade da ação dos colírios nesta população é diferente, sendo maior com Alphagan ® (Allergan, Irvine, CA) e que a ação de pico é semelhante entre os colírios (23) .…”